Alexandria Real Estate Equities (ARE) 2025: Navigating Life Science Real Estate Headwinds Amid Market Oversupply and Regulatory Uncertainty

What happened

Alexandria Real Estate Equities posted a GAAP net loss of $1.44 billion ($8.44 per diluted share) for 2025, compared to net income of $309.6 million ($1.80 per share) in 2024. The loss was primarily driven by $2.20 billion in real estate impairment charges as the company revalued properties amid deteriorating market conditions. Total revenues decreased 2.9% to $3.03 billion, reflecting lower occupancy and completed asset sales. Same Properties rental revenues declined 2.6%, with average occupancy falling to 92.5% from 95.2% in 2024. Despite the GAAP loss, funds from operations as adjusted totaled $1.53 billion ($9.01 per share), down from $1.63 billion ($9.47 per share) in 2024, reflecting the underlying operational performance excluding impairments. The company completed $1.81 billion in dispositions and sales of partial interests, significantly exceeding its initial guidance midpoint. Key lease expirations totaling 1.2 million rentable square feet with weighted-average expiration in April 2026 are expected to experience 6-24 months of downtime before re-leasing. General and administrative expenses declined sharply to $117.0 million from $168.4 million through cost-reduction initiatives. The company reduced its quarterly common stock dividend from $1.32 to $0.72 per share in Q4 2025, preserving approximately $410 million in annual liquidity to support its 2026 capital plan.

Why it matters for investors

The financial results reflect a fundamental repositioning of Alexandria's business in response to structural challenges in the life science real estate market. The sharp increase in impairment charges signals deteriorating property valuations driven by oversupply, reduced tenant demand, and higher capitalization rates. Life science space availability in Alexandria's top three markets reached 29% in 2025, up from just 4% in 2021, while tenant demand decreased more than 60% from pandemic-era peaks. This imbalance has compressed rental rates and increased lease concessions, evidenced by rising tenant improvements per rentable square foot from $26.09 in 2023 to $55.34 in 2025. The dividend reduction demonstrates management's prioritization of balance sheet strength and capital preservation over shareholder distributions in a challenging environment. The 30% reduction in general and administrative expenses shows the company's ability to adjust its cost structure, though approximately half of these savings are temporary. Looking forward, the company faces continued pressure from regulatory disruptions including FDA workforce reductions, proposed NIH funding cuts, and tariff-related cost increases. Management's 2026 guidance projects occupancy declining to approximately 88.5%, with same property net operating income expected to decrease 7.5% to 9.5%. The company's strategic focus on its Megacampus platform, which represents 78% of annual rental revenue, and its plan to complete $2.90 billion in dispositions in 2026 are critical to reducing leverage and repositioning the portfolio for eventual market recovery.

Key highlights

Alexandria Real Estate Equities owns and operates 33.7 million rentable square feet of Class A/A+ laboratory and office properties, concentrated in premier life science innovation clusters including Greater Boston, San Francisco Bay Area, San Diego, and Seattle. The company's signature Megacampus ecosystems—large-scale clustered environments exceeding one million square feet each—generated 78% of annual rental revenue and represent its core competitive differentiation. For 2025, total revenues of $3.03 billion declined 2.9% from prior year, with same property net operating income on a cash basis increasing just 0.9%. However, excluding dispositions completed after January 1, 2024, same property net operating income on a cash basis would have increased 6.2%. The company executed 4.2 million square feet of leasing during 2025, including 944,362 square feet of previously vacant space. Operating margins remained robust at 70% for the full year. Alexandria maintains a strong balance sheet with net debt and preferred stock to Adjusted EBITDA of 5.7x (Q4 2025 annualized), investment-grade credit ratings of BBB+ (S&P) and Baa1 (Moody's), and 97.2% of debt at fixed rates with weighted-average remaining term of 12.1 years. Construction spending totaled $1.44 billion in 2025, focused on highly-leased active projects, with projected spending of $1.75 billion in 2026 (midpoint of guidance). The development and redevelopment pipeline totals 3.5 million square feet under construction, with 77% concentrated within Megacampus ecosystems. Projects expected to deliver through 2026 are 86% leased or negotiating, anticipated to generate $97 million in incremental annual net operating income, while 2027-2028 deliveries are projected to contribute an additional $123 million.

Management commentary

Management acknowledged significant structural challenges facing the life science real estate sector. In response to pandemic-driven demand, substantial new laboratory supply entered the market, with availability reaching 29% in Alexandria's top three markets by year-end 2025, up from just 4% in 2021. Simultaneously, life science tenant demand moderated sharply—declining over 60% from 2021 peaks—due to prolonged biotech bear market conditions, constrained venture capital funding (at lowest levels since 2016), closed IPO windows, elevated interest rates, and intensified regulatory uncertainty. Management noted that 2025 brought an unusual convergence of macroeconomic, regulatory, policy, and political challenges including leadership disruptions at HHS, FDA workforce reductions exceeding 50% of senior staff, proposed NIH funding cuts and indirect cost caps (though the 15% cap was blocked by courts), heightened pharmaceutical pricing scrutiny, and tariff-related pressures. These factors led tenants to defer leasing commitments and expansion decisions. In response, management executed a comprehensive strategic repositioning: reducing the quarterly dividend 45% to preserve $410 million in annual liquidity, cutting general and administrative expenses 30% through headcount reductions and operational efficiencies, completing $1.81 billion in dispositions (exceeding guidance), and reducing future construction spending by over $300 million through asset sales and project reprioritization. Management emphasized that its Megacampus platform—representing 78% of rental revenue—provides differentiated competitive advantage through superior scale, strategic design, amenities, and proximity to talent, enabling the company to capture outsized market share even in challenging conditions. For 2026, management projects occupancy declining to approximately 88.5%, same property net operating income decreasing 7.5% to 9.5%, and funds from operations as adjusted of $6.25 to $6.55 per share, while targeting net debt and preferred stock to Adjusted EBITDA of 5.6x to 6.2x (Q4 2026 annualized) through disciplined capital allocation and projected dispositions of $2.90 billion.

What to watch next

Investors should monitor:

• Execution of 2026 disposition program targeting $2.90 billion (midpoint) in asset sales, with approximately $581.7 million of assets already classified as held for sale as of December 31, 2025, as successful execution is critical to reducing leverage, funding construction, and managing occupancy metrics.

• Progress on re-leasing key vacant spaces totaling 1.2 million rentable square feet with weighted-average lease expiration in April 2026, expected downtime of 6-24 months, and potential additional 1.2 million square feet of 2027 expirations with significant anticipated downtime.

• Trajectory of life science space supply and demand fundamentals in core markets, particularly whether supply influx moderates, tenant demand stabilizes, and regulatory uncertainties (FDA staffing, NIH funding, pharmaceutical pricing policies) resolve or intensify.

• Development and redevelopment pipeline performance, including lease-up progress on 3.5 million square feet under construction (64% currently leased/negotiating overall), business strategy decisions on four projects totaling 1.2 million square feet under evaluation, and realization of projected $97 million incremental annual net operating income from 2026 deliveries.

• Trends in rental rates, tenant improvement costs, and lease concessions to assess whether negative pricing momentum continues or stabilizes, and whether revenue- and non-revenue-enhancing capital expenditures remain elevated above historical levels or normalize over time.

This summary is based solely on excerpts from the company's Form 10-K filing.